Results 31 to 40 of about 944,744 (294)

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Journal for ImmunoTherapy of Cancer, 2019
Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor ...
Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John-William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau   +40 more
doaj   +1 more source

Role of noninvasive molecular imaging in determining response [PDF]

, 2018
The intersection of immunotherapy and radiation oncology is a rapidly evolving area of preclinical and clinical investigation. The strategy of combining radiation and immunotherapy to enhance local and systemic antitumor immune responses is intriguing ...
Marciscano, Ariel E, Thorek, Daniel L.J.
core   +2 more sources

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Journal for ImmunoTherapy of Cancer, 2019
.
Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John-William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz Jr, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau   +40 more
doaj   +1 more source

Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

OncoImmunology, 2023
BO-112 is a poly I:C-based viral mimetic that exerts anti-tumor efficacy when intratumorally delivered in mouse models. Intratumoral BO-112 synergizes in mice with systemic anti-PD-1 mAbs and this combination has attained efficacy in PD1-refractory ...
Maite Alvarez, Carmen Molina, Saray Garasa, Maria C. Ochoa, Maria E Rodriguez-Ruiz, Gabriel Gomis, Assunta Cirella, Irene Olivera, Javier Glez-Vaz, Jose Gonzalez-Gomariz, carlos luri-Rey, arantza azpilikueta, Elixabet Bolaños, Alvaro Teijeira, Pedro Berraondo, Marisol Quintero, Ignacio Melero   +16 more
doaj   +1 more source

Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia [PDF]

, 2017
Interactions between killer-immunoglobulin-like receptors (KIRs) and their HLA class I ligands are instrumental in natural killer (NK) cell regulation and protect normal tissue from NK cell attack.
Aurelius, J., Bernson, E., Brune, M., Foà, R., Hallner, A., Hellstrand, K., Kiffin, R., Martner, A., Rydström, A., Sander, F. E., Thorén, F. B., Werlenius, O., Wilsson, O.   +12 more
core   +1 more source

The alarmin IL33 orchestrates type 2 immune-mediated control of thymus regeneration

Nature Communications, 2023
As the primary site of T-cell development, the thymus dictates immune competency of the host. The rates of thymus function are not constant, and thymus regeneration is essential to restore new T-cell production following tissue damage from environmental ...
Emilie J. Cosway, Kieran D. James, Andrea J. White, Sonia M. Parnell, Andrea Bacon, Andrew N. J. McKenzie, W. E. Jenkinson, Graham Anderson   +7 more
doaj   +1 more source

Nanomaterials in tumor immunotherapy: new strategies and challenges

Molecular Cancer, 2023
Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality of anti-tumor therapy with significant clinical efficacy and advantages compared to chemotherapy ...
Xudong Zhu, Shenglong Li
semanticscholar   +1 more source

The future outlook on allergen immunotherapy in children: 2018 and beyond. [PDF]

, 2018
Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases.
Arasi S, Corsello G, Pajno GB, Villani A
core   +2 more sources

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers

Molecular Cancer, 2023
In recent years, breakthroughs have been made in tumor immunotherapy. However, tumor immunotherapy, particularly anti-PD-1/PD-L1 immune checkpoint inhibitors, is effective in only a small percentage of patients in solid cancer.
Liping Pei, Yang Liu, Lin Liu, Shuochen Gao, Xu Gao, Yudi Feng, Zhenqiang Sun, Yan Zhang, Chengzeng Wang   +8 more
semanticscholar   +1 more source

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

New England Journal of Medicine, 2010
BACKGROUND Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer.
P. Kantoff, C. Higano, N. Shore, E. Berger, E. Small, D. Penson, C. Redfern, A. Ferrari, R. Dreicer, R. Sims, Yi Xu, M. Frohlich, P. Schellhammer   +12 more
semanticscholar   +1 more source